Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Coherus BioSciences, Inc. CHRS
$4.87
-$0.3 (-6.26%)
На 18:00, 12 мая 2023
+84.80%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
428890410.00000000
-
week52high
14.11
-
week52low
5.17
-
Revenue
211042000
-
P/E TTM
-2
-
Beta
0.94602000
-
EPS
-3.80000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 20:00
Описание компании
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Mizuho | Buy | Buy | 16 авг 2022 г. |
| UBS | Neutral | 14 июн 2022 г. | |
| Mizuho | Buy | Buy | 20 мая 2022 г. |
| Barclays | Overweight | Overweight | 09 мая 2022 г. |
| JP Morgan | Neutral | Overweight | 07 мар 2022 г. |
| Mizuho | Buy | Buy | 16 ноя 2022 г. |
| JP Morgan | Neutral | Neutral | 14 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| McMichael Bryan J | A | 26386 | 12500 | 20 янв 2023 г. |
| Lanfear Dennis M | A | 654853 | 86250 | 20 янв 2023 г. |
| Stilwell McDavid | A | 104243 | 40000 | 20 янв 2023 г. |
| Vexler Vladimir | A | 131323 | 40000 | 20 янв 2023 г. |
| Vexler Vladimir | D | 91323 | 3602 | 11 янв 2023 г. |
| Vexler Vladimir | D | 94925 | 3602 | 10 янв 2023 г. |
| McMichael Bryan J | D | 13886 | 1699 | 07 янв 2023 г. |
| Lanfear Dennis M | A | 402500 | 402500 | 05 янв 2023 г. |
| Stilwell McDavid | A | 80000 | 80000 | 04 янв 2023 г. |
| Stilwell McDavid | D | 64243 | 5437 | 04 янв 2023 г. |
Новостная лента
Coherus BioSciences, Inc. (CHRS) Q1 2023 Earnings Call Transcript
Seeking Alpha
08 мая 2023 г. в 21:40
Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Marek Ciszewski - Investor Relations Denny Lanfear - Chief Executive Officer Theresa Lavallee - Chief Development Officer Rosh Dias - Chief Medical Officer Paul Reider - Chief Commercial Officer McDavid Stilwell - Chief Financial Officer Conference Call Participants Robyn Karnauskas - Truist Securities Salim Syed - Mizuho Mike Nedelcovych - TD Cowen Douglas Tsao - H.C. Wainwright Ash Verma - UBS Chris Schott - JPM Operator Good day and thank you for standing by.
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research
08 мая 2023 г. в 19:02
Coherus BioSciences (CHRS) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $1.24 per share a year ago.
Coherus BioSciences to Present at Upcoming Investor Conferences in May
GlobeNewsWire
04 мая 2023 г. в 16:30
REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences:
Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023
GlobeNewsWire
01 мая 2023 г. в 16:07
REDWOOD CITY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced its first quarter 2023 financial results will be released after market close on Monday, May 8, 2023. Starting at 5:00 pm ET on May 8, 2023, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.
Coherus Still Looks Good, Multiple Catalysts This Year (Rating Downgrade)
Seeking Alpha
28 апр 2023 г. в 08:00
Coherus Still Looks Good, Multiple Catalysts This Year (Rating Downgrade).